Aims The efficacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …

Background: Sacubitril/valsartan improves heart failure (HF) outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). However, randomized controlled trials (RCTs) …

Background Compared with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers, Sacubitril/Valsartan has been reported to have superior results. However …

Objective• Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically
significant condition characterized by limited treatment options. In this context, the objective …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Background Controversy has persisted over the clinical benefits of low‐dose
sacubitril/valsartan in patients with heart failure (HF). Hypothesis Low‐dose …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Background The effect of sacubitril-valsartan in heart failure patients with mid-range
(HFmEF) and preserved (HFpEF) ejection fractions remains unclear. This study aimed to …